6505--Metformin IR Tablets

The Department of Veterans Affairs National Acquisition Center is seeking to establish a contract for Metformin Hydrochloride Immediate Release (IR) Tablets in various package sizes and strengths, including 1000mg and 500mg tablets in 100, 500, and 1000 tablet bottle configurations. The solicitation targets pharmaceutical manufacturers capable of providing a unique 11-digit National Drug Code (NDC) number and maintaining FDA-approved manufacturing facilities with current Good Manufacturing Practices (cGMP) certification. Offerors must submit comprehensive proposals including manufacturer commitment letters and pricing for all line items across a base year and four one-year option periods, with a mandatory 0.5% Cost Recovery Fee. The critical proposal submission deadline is April 29, 2025, at 2:30 PM CDT, with an anticipated contract award date of April 14, 2025. Evaluation will likely focus on technical compliance, regulatory requirements, manufacturing capabilities, and pricing competitiveness.

The solicitation is open to small businesses with a size standard of 1,300 employees and does not have a specific small business set-aside. The contract will be distributed through VA and Department of Defense Pharmaceutical Prime Vendor programs, with participating agencies including VA facilities, DoD, Indian Health Service, Bureau of Prisons, and State Veterans Homes. Annual quantities range from approximately 2,369 to 354,062 bottles, providing significant potential volume for the selected contractor. While specific award value is not explicitly stated, the broad distribution and high annual quantities suggest a substantial contract opportunity. The place of performance will encompass multiple federal healthcare facilities across the United States, with product distribution managed through established pharmaceutical prime vendor channels. Qualified vendors must demonstrate the ability to consistently supply Metformin IR Tablets meeting stringent federal healthcare procurement standards.